pubmed-article:20383692 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20383692 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
pubmed-article:20383692 | lifeskim:mentions | umls-concept:C2239176 | lld:lifeskim |
pubmed-article:20383692 | lifeskim:mentions | umls-concept:C0040648 | lld:lifeskim |
pubmed-article:20383692 | lifeskim:mentions | umls-concept:C2347610 | lld:lifeskim |
pubmed-article:20383692 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
pubmed-article:20383692 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
pubmed-article:20383692 | pubmed:issue | 8 | lld:pubmed |
pubmed-article:20383692 | pubmed:dateCreated | 2010-7-9 | lld:pubmed |
pubmed-article:20383692 | pubmed:abstractText | Hepatocellular carcinoma (HCC) is a hypervascularized tumor entity with association of arterial vessel density with poor prognosis. The hypoxia-inducible transcription factor HIF-1alpha represents a pivotal regulator of angiogenesis and is thought to determine the angiogenic nature of HCC. However, the precise role of HIF-1alpha during the pathogenesis of HCC remains elusive. We established a functional inactivation of HIF-1alpha in vitro and in vivo via RNAi and Cre/loxP-mediated recombination, respectively, to determine HIF-1alpha's role for tumor growth and chemosensitivity in transgenic and orthotopic murine HCC models. HIF-1alpha-deficient HCC cells displayed significantly reduced anchorage-independent growth and enhanced sensitivity toward etoposide, while basic cellular proliferation was unaffected. Analysis of gross tumor growth failed to detect reduced growth of HIF-1alpha-deficient tumors in the orthotopic and the transgenic HCC model, respectively. In line with the in vitro data, treatment of HIF-1alpha-deficient tumors with etoposide resulted in greater antiproliferative efficacy when compared to wild-type mice. Taken together, our study does not support a pivotal role of HIF-1alpha for tumor growth and angiogenesis in two murine HCC models. However, our data point toward a significant function of HIF-1alpha in determining chemosensitivity of HCC and therefore warrant validation of HIF-1alpha-inhibitors as adjuvant therapeutic agents in clinical studies of human HCC. | lld:pubmed |
pubmed-article:20383692 | pubmed:language | eng | lld:pubmed |
pubmed-article:20383692 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20383692 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:20383692 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20383692 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20383692 | pubmed:month | Aug | lld:pubmed |
pubmed-article:20383692 | pubmed:issn | 1432-1440 | lld:pubmed |
pubmed-article:20383692 | pubmed:author | pubmed-author:WiedenmannBer... | lld:pubmed |
pubmed-article:20383692 | pubmed:author | pubmed-author:SchmitzVolker... | lld:pubmed |
pubmed-article:20383692 | pubmed:author | pubmed-author:LoddenkemperC... | lld:pubmed |
pubmed-article:20383692 | pubmed:author | pubmed-author:CramerThorste... | lld:pubmed |
pubmed-article:20383692 | pubmed:author | pubmed-author:DupuyEvelyneE | lld:pubmed |
pubmed-article:20383692 | pubmed:author | pubmed-author:RaskopfEsther... | lld:pubmed |
pubmed-article:20383692 | pubmed:author | pubmed-author:KühlAnjaA | lld:pubmed |
pubmed-article:20383692 | pubmed:author | pubmed-author:DaskalowKatja... | lld:pubmed |
pubmed-article:20383692 | pubmed:author | pubmed-author:RohwerNadineN | lld:pubmed |
pubmed-article:20383692 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:20383692 | pubmed:volume | 88 | lld:pubmed |
pubmed-article:20383692 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20383692 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20383692 | pubmed:pagination | 817-27 | lld:pubmed |
pubmed-article:20383692 | pubmed:dateRevised | 2011-7-8 | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:meshHeading | pubmed-meshheading:20383692... | lld:pubmed |
pubmed-article:20383692 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20383692 | pubmed:articleTitle | Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. | lld:pubmed |
pubmed-article:20383692 | pubmed:affiliation | Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany. | lld:pubmed |
pubmed-article:20383692 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:20383692 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
entrez-gene:3091 | entrezgene:pubmed | pubmed-article:20383692 | lld:entrezgene |
entrez-gene:15251 | entrezgene:pubmed | pubmed-article:20383692 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20383692 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20383692 | lld:entrezgene |